Overview
Seer Inc. offers the Proteograph product suite, an integrated platform for deep, unbiased plasma proteomics using proprietary engineered nanoparticles, automation instruments, and analysis software. It enables large-scale proteomic profiling for biomarker discovery in areas like cancer, neurodegenerative, and metabolic diseases. The technology complements mass spectrometry systems, with a co-marketing agreement with Thermo Fisher Scientific for integration with Orbitrap Astral mass spectrometers.
Frequently asked questions
- What are the core capabilities of Seer's Proteograph platform?
- The Proteograph suite provides deep, unbiased proteomic profiling of plasma and serum at scale, using engineered nanoparticles to access the full proteome dynamic range, combined with automation and analysis software for biomarker discovery.
- What is the regulatory status of Seer's products?
- Proteograph is designated for research use only (RUO), though Seer has secured certifications to advance toward clinical testing applications.
- What geographies does Seer serve and are there key partnerships?
- Seer operates globally, with Thermo Fisher Scientific's worldwide sales force promoting Proteograph via a co-marketing agreement starting early 2025; it integrates with systems like Orbitrap Astral and Bruker timsTOF.